A member of the Rutgers Institute for Health, Health Care Policy, and Aging Research served as lead author of a recent study showing the potential of telehealth services to address health care disruption among individuals with multiple sclerosis.
In tackling high rates of health care disruption among individuals with multiple sclerosis (MS), a study led by investigators from the Rutgers Institute for Health, Health Care Policy, and Aging Research (IFH) showed that people with MS were more likely to utilize telehealth services than people without the condition.
The study was published in Archives of Physical Medicine and Rehabilitation, with research also conducted by investigators of Kessler Foundation, Rutgers New Jersey Medical School, and New York University
“The findings suggest that telehealth services were well liked during the pandemic. Because many individuals with MS have physical disability that may make travel more difficult, temporary expansions of telehealth coverage should be made permanent after the pandemic in order to expand access and reduce health care disparities,” said lead study author Michelle Chen, a core member of Rutgers IFH, and neurology instructor at Robert Wood Johnson Medical School.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More